{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:48:13Z","timestamp":1790023693176,"version":"4.0.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.diagmicrobio.2009.08.020","type":"journal-article","created":{"date-parts":[[2009,10,16]],"date-time":"2009-10-16T08:30:41Z","timestamp":1255681841000},"page":"414-426","source":"Crossref","is-referenced-by-count":148,"title":["Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999\u20132008)"],"prefix":"10.1016","volume":"65","author":[{"given":"Paul R.","family":"Rhomberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/JCM.01351-06","article-title":"blaVIM-2 and blaVIM-7 carbapenemase-producing Pseudomonas aeruginosa isolates detected in a tertiary care medical center in the United States: report from the MYSTIC program","volume":"45","author":"Aboufaycal","year":"2007","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijantimicag.2009.02.002","article-title":"Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997\u20132006","volume":"34","author":"Adam","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib3","first-page":"388","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"15","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1128\/AAC.41.3.563","article-title":"Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the loss of an outer membrane protein","volume":"41","author":"Bradford","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1086\/421495","article-title":"Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City","volume":"39","author":"Bradford","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib6","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/archinte.165.12.1430","article-title":"Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium","volume":"165","author":"Bratu","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib7","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/jac\/46.6.895","article-title":"Emergence of imipenem resistance in Klebsiella pneumoniae owing to combination of plasmid-mediated CMY-4 and permeability alteration","volume":"46","author":"Cao","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/mdr.2008.0827","article-title":"Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007).","volume":"14","author":"Castanheira","year":"2008","journal-title":"Microb. Drug Resist."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib9","series-title":"Development of in vitro susceptibility testing criteria and quality control parameters\u2014third edition, M23-A3","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2008"},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib10","series-title":"Performance standards for antimicrobial disk susceptibility tests; approved standard\u201410th edition, M02-A10","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2009"},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib11","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014eighth edition, M07-A8","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2009"},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib12","series-title":"Performance standards for antimicrobial susceptibility testing: 19th informational supplement (M100-S19)","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2009"},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib13","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1345\/aph.1L473","article-title":"Comparison of 2002\u20132006 OPTAMA programs for US hospitals: focus on gram-negative resistance","volume":"43","author":"Crandon","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.diagmicrobio.2006.07.004","article-title":"Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999\u20132005)","volume":"56","author":"Deshpande","year":"2006","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib15","author":"EARSS"},{"issue":"Suppl. A","key":"10.1016\/j.diagmicrobio.2009.08.020_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/36.suppl_A.1","article-title":"Meropenem: a microbiological overview","volume":"36","author":"Edwards","year":"1995","journal-title":"J. Antimicrob. Chemother."},{"issue":"Suppl. 2","key":"10.1016\/j.diagmicrobio.2009.08.020_bib17","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/jac\/dki297","article-title":"The Alexander Project: the benefits from a decade of surveillance","volume":"56","author":"Felmingham","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1086\/520193","article-title":"Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals.","volume":"29","author":"Fridkin","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0732-8893(00)00222-4","article-title":"Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f beta-lactamase (SME-1) in the United States: results from the MYSTIC Programme","volume":"39","author":"Gales","year":"2001","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"Suppl. 6","key":"10.1016\/j.diagmicrobio.2009.08.020_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/1120009X.2004.11782399","article-title":"PROTEKT years 1\u20133 (1999\u20132002): study design and methodology","volume":"16","author":"Harding","year":"2004","journal-title":"J. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib21","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1128\/AAC.48.11.4438-4440.2004","article-title":"Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp","volume":"48","author":"Hossain","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib22","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1086\/598244","article-title":"Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns","volume":"30","author":"Hussein","year":"2009","journal-title":"Infect. Control. Hosp. Epidemiol."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0732-8893(96)00099-5","article-title":"The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance.","volume":"25","author":"Jones","year":"1996","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"Suppl. T2","key":"10.1016\/j.diagmicrobio.2009.08.020_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/46.suppl_2.1","article-title":"Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection","volume":"46","author":"Jones","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2003-37923","article-title":"Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997\u20132001)","volume":"24","author":"Jones","year":"2003","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0732-8893(01)00318-2","article-title":"Determining the value of antimicrobial surveillance programs","volume":"41","author":"Jones","year":"2001","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0732-8893(01)00343-1","article-title":"Ciprofloxacin as broad-spectrum empiric therapy\u2014are fluoroquinolones still viable monotherapeutic agents compared with beta-lactams: data from the MYSTIC Program (US)?","volume":"42","author":"Jones","year":"2002","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib28","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0924-8579(02)00210-8","article-title":"A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant Gram-negative bacilli including bacteraemic Salmonella spp.: initial studies for the MYSTIC programme in India","volume":"20","author":"Jones","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.diagmicrobio.2004.03.016","article-title":"Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999\u20132003)","volume":"49","author":"Jones","year":"2004","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.diagmicrobio.2005.10.006","article-title":"An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997\u20132004","volume":"53","author":"Jones","year":"2005","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.diagmicrobio.2008.01.017","article-title":"Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance","volume":"61","author":"Jones","year":"2008","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib32","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/0091270003257225","article-title":"Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem","volume":"43","author":"Kuti","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib33","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1128\/AAC.48.7.2464-2470.2004","article-title":"Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002","volume":"48","author":"Kuti","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib34","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/archinte.162.13.1515","article-title":"Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned.","volume":"162","author":"Landman","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib35","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0091270006291035","article-title":"Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients","volume":"46","author":"Li","year":"2006","journal-title":"J. Clin. Pharmacol."},{"issue":"Suppl. T2","key":"10.1016\/j.diagmicrobio.2009.08.020_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/jac\/46.suppl_2.53","article-title":"Surveillance studies: how can they help the management of infection?","volume":"46","author":"Masterton","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0732-8893(02)00466-2","article-title":"Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories","volume":"44","author":"Mathai","year":"2002","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib39","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1128\/AAC.47.4.1297-1300.2003","article-title":"Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2","volume":"47","author":"Miriagou","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib40","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkh039","article-title":"Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999\u20132001)","volume":"53","author":"Mutnick","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib38","series-title":"Merrem","author":"Package Insert","year":"2007"},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib41","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1046\/j.1469-0691.2000.00107.x","article-title":"Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs)","volume":"6","author":"Paterson","year":"2000","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib42","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0732-8893(97)00065-5","article-title":"A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide","volume":"28","author":"Pfaller","year":"1997","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"Suppl. T2","key":"10.1016\/j.diagmicrobio.2009.08.020_bib43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/46.suppl_2.25","article-title":"MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas)","volume":"46","author":"Pfaller","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0732-8893(01)00319-4","article-title":"Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA)","volume":"41","author":"Pfaller","year":"2001","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib45","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1128\/AAC.44.11.3035-3039.2000","article-title":"SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains","volume":"44","author":"Queenan","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib46","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.diagmicrobio.2006.07.009","article-title":"Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC Program report from the United States component (2005)","volume":"57","author":"Rhomberg","year":"2007","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib47","first-page":"2","article-title":"Antibiotic resistance in hospitalized patients: MYSTIC Program (1999\u20132002)","volume":"7","author":"Rhomberg","year":"2003","journal-title":"Antibiot. Clin."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijantimicag.2003.05.010","article-title":"Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres","volume":"23","author":"Rhomberg","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib49","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.diagmicrobio.2004.02.003","article-title":"Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003)","volume":"49","author":"Rhomberg","year":"2004","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib50","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1179\/joc.2005.17.5.459","article-title":"Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004)","volume":"17","author":"Rhomberg","year":"2005","journal-title":"J. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.diagmicrobio.2005.12.009","article-title":"Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA)","volume":"56","author":"Rhomberg","year":"2006","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib52","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.diagmicrobio.2005.10.010","article-title":"Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States","volume":"54","author":"Rhomberg","year":"2006","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib53","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.diagmicrobio.2007.05.009","article-title":"Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006)","volume":"59","author":"Rhomberg","year":"2007","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib54","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jac\/dkp139","article-title":"Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.","volume":"64","author":"Roberts","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib55","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1128\/JCM.34.12.2909-2913.1996","article-title":"PCR detection of metallo-beta-lactamase gene (blaIMP) in gram-negative rods resistant to broad-spectrum beta-lactams","volume":"34","author":"Senda","year":"1996","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib56","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1128\/AAC.40.2.349","article-title":"Multifocal outbreaks of metallo-beta-lactamase\u2013producing Pseudomonas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenems","volume":"40","author":"Senda","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1086\/524891","article-title":"The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America","volume":"46","author":"Spellberg","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib58","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1128\/JCM.33.9.2233-2239.1995","article-title":"Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing","volume":"33","author":"Tenover","year":"1995","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1128\/AAC.48.1.329-332.2004","article-title":"blaVIM-7, an evolutionarily distinct metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States","volume":"48","author":"Toleman","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl. T2","key":"10.1016\/j.diagmicrobio.2009.08.020_bib60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/46.suppl_2.9","article-title":"MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview","volume":"46","author":"Turner","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib61","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.diagmicrobio.2004.07.004","article-title":"Susceptibility of meropenem and comparators tested against 30,634 Enterobacteriaceae isolated in the MYSTIC Programme (1997\u20132003)","volume":"50","author":"Turner","year":"2004","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib62","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.diagmicrobio.2005.10.005","article-title":"Use of a program-specific website to disseminate surveillance data obtained from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Study","volume":"53","author":"Turner","year":"2005","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib63","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.diagmicrobio.2008.11.004","article-title":"MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates","volume":"63","author":"Turner","year":"2009","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib64","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0924-8579(99)00115-6","article-title":"The MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) programme","volume":"13","author":"Turner","year":"1999","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib65","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00003495-199550010-00007","article-title":"Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy","volume":"50","author":"Wisemann","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib67","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.48.12.4793-4799.2004","article-title":"Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center.","volume":"48","author":"Woodford","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib66","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/jac\/dkl514","article-title":"In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp","volume":"59","author":"Woodford","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.08.020_bib68","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1128\/AAC.45.4.1151-1161.2001","article-title":"Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae","volume":"45","author":"Yigit","year":"2001","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889309003629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889309003629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T02:26:44Z","timestamp":1590200804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889309003629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0732889309003629"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2009.08.020","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}